Copper in medicine

Current Opinion in Chemical Biology

Volumn 7, Issue 2, 2003, Pages 207-212

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; TETRATHIOMOLYBDIC ACID;

ACERULOPLASMINEMIA; ALZHEIMER DISEASE; ANGIOGENESIS; AUTOSOMAL RECESSIVE DISORDER; CLINICAL TRIAL; COPPER DEFICIENCY; COPPER METABOLISM; FIBROSIS; GENE MUTATION; HUMAN; INFLAMMATION; INTOXICATION; MENKES SYNDROME; NONHUMAN; RETINOPATHY; REVIEW; SENILE PLAQUE; WILSON DISEASE;

RODENTIA;

EID: 0037399007     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00018-8     Document Type: Review

References (46)

1. Bull P., Thomas G., Rommens J., Forbes J., Cox D. The Wilson's disease gene is a putative copper transporting P-type ATPase similar to the Menke's gene. Nature Genet. 5:1993;327-337.
2. Brewer G. Recognition, diagnosis, and management of Wilson's disease. Exp. Biol. Med. 223:2000;39-46 A recent review on clinical aspects of Wilson's disease.
3. Brewer G: Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston: Kluwer Academic Publishers; 2001.
4. Cox D, Roberts E: Wilson's disease. GeneClinics, University of Washington, Seattle. On World Wide Web URL: http://www.geneclinics.org/profiles/wilson/details.html .
5. Brewer G., Dick R., Johnson V., Brunberg J., Kluin K., Fink J. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J. Lab. Clin. Med. 132:1998;264-278.
6. Brewer G., Yuzbasiyan-Gurkan V. Wilson's disease. Medicine. 71:1992;139-164.
7. Brewer G., Johnson V., Dick R., Wang Y., Kluin K., Fink J., Brunberg J. Treatment of Wilson's disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 53:1996;1017-1025.
8. Brewer G, Hedera P, Kluin K, Carlson M, Askari F, Dick R, Sitterly J, Fink J: Treatment of Wilson's disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003, in press.
9. Brewer G., Terry C., Aisen A., Hill G. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch. Neurol. 44:1987;490-493.
10. Askari F, Greenson J, Dick R, Johnson V, Brewer G: Treatment of Wilson's disease with zinc XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2002, in press.
11. Brewer G: Wilson's Disease for the Patient and Family: A Patients Guide to Wilson's Disease and Frequently asked Questions about Copper. Philadelphia: Xlibris; 2001.
12. Mercer J., Livingston J., Hall B., Paynter J., Begy C., Chandrasekharappa S., Lockhart P., Grimes A., Bhave M., Siemieniak D.et al. Isolation of a partial candidate gene for Menke's disease by positional cloning. Nat. Genet. 3:1993;20-25.
13. Llanos R., Mercer J. The molecular basis of copper homeostasis and copper-related disorders. DNA Cell Biol. 21:2002;259-270 A recent review that summarizes both basic and clinical aspects of copper-related diseases.
14. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., Hiyamuta S., Ikeda S., Norikazu S., Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9:1995;267-272.
15. Müller T., Feichtinger H., Berger H., Müller W. Endemic tyrolean infantile cirrhosis: an exogenetic disorder. Lancet. 347:1996;877-880.
16. Tanner M., Kantarjian A., Bhave S., Pandit A. Early introduction of copper-contaminated animal milk feeds as a possible cause of Indian childhood cirrhosis. Lancet. 2:1983;992-995.
17. Müller T., Müller W., Freichtinger H. Idiopathic copper toxicosis. Am. J. Clin. Nutr. 67(Suppl.):1998;1082S-1086S.
18. Brewer G. Editorial: is heterozygosity for a Wilson's disease gene defect an important underlying cause of infantile and childhood copper toxicosis syndromes? J. Trace El Exp. Med. 13:2000;249-254 An editorial that asks if heterozygosity for a defect in the Wilson's gene, plus high copper ingestion, could account for these mysterious afflictions.
19. Van de Sluis B., Rothuizen J., Pearson P., Van Oost B., Wijmenga C. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum. Mol. Genet. 11:2002;165-173 A recent paper which identities MURR1 as a likely cause of canine copper toxicosis, which, if correct, adds this gene to the list of genes that could cause a human disease.
20. Zhou B., Gitschier J. hCTR1: A human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. U.S.A. 94:1999;7481-7486.
21. Lee J., Prohaska J., Thiele D. Essential role for mammalian copper transporter CTR1 in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. U.S.A. 98:2001;6842-6847 This paper establishes CTR1 as a critical gene for life in mice, thus making it a candidate for causing human disease.
22. •].
23. Puig S., Thiele D. Molecular mechanisms of copper uptake and distribution. Curr. Opin. Chem. Biol. 6:2002;171-180.
24. Arnesano F., Banci L., Bertini I., Ciofi-Baffoni S., Molteni E., Huffman D., O'Halloran T. Metallochaperones and metal-transporting ATPases: a comparative analysis of sequences and structures. Gen. Res. 12:2002;255-271 This paper provides a recent summary of the key roles of copper chaperones and the molecules they subserve.
25. ••]).
26. White A., Multhaup G., Maher F., Bellingham S., Camakaris J., Zheng H., Bush A., Beyreuther K., Masters C., Cappai R. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J. Neurosci. 19:1999;9170-9179.
27. Cherny R., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W.et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676 This important paper presents successful results in preventing amyloid precipitation in an Alzheimer's mouse model.
28. Lyons T., Nerisissian A., Huang H., Yeom H., Nishida C., Graden J., Gralla E., Valentine J. The metal binding properties of the zinc site of yeast copper-zinc superoxide dismutase: implications for amyotrophic lateral sclerosis. J. Biol. Inorg. Chem. 5:2000;189-203.
29. The Committee on Copper in Drinking Water: Copper in Drinking Water. Washington, DC: Nat Acad Press, 2000.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
31. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 46:1986;467-473.
32. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control. 6:1999;436-458.
33. Beckner M. Factors promoting tumor angiogenesis. Cancer Invest. 17:1999;594-623.
34. Parke A., Battacherjee P., Palmer R., Lazarus N. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am. J. Clin. Path. 137:1988;1121-1142.
35. 1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:1982;475-482.
36. Brem S., Zagzag D., Tsanaclis A., Gatley S., Elkouby M., Brein S. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Path. 137:1990;1121-1147.
37. Brem S., Tsanaclis A., Zagzag D. Anticopper treatment inhibits pseudopdial protrusion and invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery. 26:1990;391-396.
38. Brewer G. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. EBM. 226:2001;665-673 A recent review that summarizes anticopper therapy ranging from Wilson's disease to recent uses and ideas in anticancer and antiangiogenic therapy.
39. Pan Q., Kleer C., van Golen K., Irani J., Bottema K., Bias C., De Carvalho M., Mesri E., Robins D., Dick R.et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62:2002;4854-4859 The latest on how TM anticopper therapy works in various animal models and at the basic level of cytokine signaling.
40. Cox C., Teknos T., Barrios M., Brewer G., Dick R., Merajver S. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope. 111:2001;696-701.
41. Khan M., Miller M., Taylor J., Navkiranjit K., Dick R., van Golen K., Brewer G., Merajver S. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia. 4:2002;1-7.
42. van Golen K., Bao L., Brewer G., Pienta K., Karadt J., Livant D., Merajver S. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia. 4:2002;373-379.
43. Brewer G., Dick R., Grover D., LeClaire V., Tseng M., Wicha M., Pienta K., Redman B., Thierry J., Sondak V.et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin. Cancer Res. 6:2000;1-10 The first clinical paper on the use of TM anticopper therapy against cancer.
44. Brewer G., Phan S. Tetrathiomolybdate anticopper therapy protects against bleomycin-pulmonary fibrosis in mice. J. Invest. Med. 50:2002;227A Only an abstract, but the first publication of a completely new use of TM anticopper therapy against a disease of fibrosis and inflammation in the mouse lung.
45. ••], except involving a disease of inflammation and fibrosis in the mouse liver.
46. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH: Tetrathiomolybdate therapy protects against bleomycin-pulmonary fibrosis in mice. J Lab Clin Med 2003, in press.